Next-generation DNA sequencing is rapidly becoming an indispensable tool for genome-directed cancer diagnostics, but next-generation RNA sequencing (RNA-seq) is currently not standardly used in clinical diagnostics for expression assessment. However, multigene RNA diagnostic assays are used increasingly in the routine diagnosis of early-stage breast cancer. Two of the most widely used tests are currently available only as a central laboratory service, which limits their clinical use. We evaluated the use of RNA-seq as a decentralized method to perform such tests. The MammaPrint and BluePrint RNA-seq tests were found to be equivalent to the clinically validated microarray tests. The RNA-seq tests were highly reproducible when performed in different locations and were stable over time. The MammaPrint RNA-seq test was clinically validated. Our data demonstrate that RNA-seq can be used as a decentralized platform, yielding results substantially equivalent to results derived from the predicate diagnostic device.
Next-generation DNA sequencing is rapidly becoming an indispensable tool for genome-directed cancer diagnostics, but next-generation RNA sequencing (RNA-seq) is currently not standardly used in clinical diagnostics for expression assessment. However, multigene RNA diagnostic assays are used increasingly in the routine diagnosis of early-stage breast cancer. Two of the most widely used tests are currently available only as a central laboratory service, which limits their clinical use. We evaluated the use of RNA-seq as a decentralized method to perform such tests. The MammaPrint and BluePrint RNA-seq tests were found to be equivalent to the clinically validated microarray tests. The RNA-seq tests were highly reproducible when performed in different locations and were stable over time. The MammaPrint RNA-seq test was clinically validated. Our data demonstrate that RNA-seq can be used as a decentralized platform, yielding results substantially equivalent to results derived from the predicate diagnostic device. In Q7 recent years, RNA-sequencing (RNA-seq) technology has become the standard for transcriptome analysis because of its flexibility, sensitivity, and accuracy in measuring gene expression. RNA-seq is a technology in which cDNA is derived from RNA, followed by library construction and massively parallel deep sequencing. 1 RNA-seq is the nextgeneration sequencing (NGS) counterpart of microarrays. However, unlike microarray, RNA-seq provides not only an in-depth view of transcript abundance, but also confers the ability to detect novel RNA transcript variants. 2 From a technical perspective, RNA-seq has proved to be highly reproducible and has low background. Considering these characteristics, RNA-seq has the potential to improve clinical diagnostics for a wide range of diseases, including cancer. To introduce the use of this technology in clinical practice, efforts are ongoing to establish reference standards and best practices for RNA-seq as a clinical test. 2 MammaPrint was one of the first gene-expressionebased diagnostic tests introduced into the clinical management of breast cancer 3e7 and the first in vitro diagnostic multivariate index assay using gene expression that obtained US Food and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 Drug Administration (FDA) 510(k) clearances for both freshfrozen (FF) and formalin-fixed, paraffin-embedded (FFPE) tissue. 8 Extensive validation studies and, above all, the recent MINDACT
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clinical trial 9 have demonstrated the clinical utility of MammaPrint at the highest level of clinical evidence (level 1A), making it a unique example of a microarray-based, clinical diagnostic test that helps guide physicians in adjuvant treatment decisions for early-stage breast cancer patients. Specifically, MammaPrint determines the expression of 70 signature genes and stratifies early-stage breast cancer patients at low and high risk for developing distant metastases within 5 years after diagnosis. A second microarray test for breast cancer is BluePrint, which measures the expression of 80 signature genes to reveal breast cancer subtypes (ie, luminal, HER2
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, and basal types). 10, 11 Currently, MammaPrint and BluePrint tests are performed at central laboratories in the Netherlands and United States using microarray technology. With a centralized setting, it is difficult to serve countries with legal restrictions on sending patient material outside the country; furthermore, reimbursement often requires local processing and forms a practical obstacle to clinical implementation of these tests. Therefore, decentralized diagnostic tests would offer to physicians an in-house solution, ideally without compromising the level of clinical validity. RNA-seq NGS technology is highly reproducible and currently easier to implement than microarray in preexisting infrastructure and experimental workflows because of the increased use of RNA-seq technology in many laboratories worldwide. In addition, RNA NGS shows good performance with RNA derived from FFPE tissues, even from small amounts of starting material. 12, 13 Herein, we evaluate the use of RNA NGSebased technology to perform clinical diagnostic testing, using the MammaPrint/BluePrint FFPE microarraybased assay as an example.
Several NGS technologies are available to date, including ion semiconductor sequencing, 14 single-molecule real-time sequencing, 15 nanopore sequencing, 16 and sequencing by synthesis. 17 The sequencing-by-synthesis technology accounts for the largest share of the market, mostly because of the development of new and advanced NGS platforms and the increasing demand for the systems (including the HiSeq series and MiSeq) of Illumina (Hayward, CA). A targeted RNA-seq approach on the Illumina NGS technology that combines the RNA (cDNA) library preparation with the enrichment of our MammaPrint/BluePrint transcripts of interest using complementary capture probes was chosen. More important, such a targeted RNA NGS approach does not rely on poly-A tail enrichment or use ribosomal RNA depletion (eg, Ribo-Zero), and it can be reliably applied on degraded and cross-linked RNAs, such as those from FFPE tissues. 13 The translation of a diagnostic test from one technology platform to another one requires a series of experiments that assess the analytical and clinical performance of the newly developed test with respect to the standard technology. Therefore, different validation experiments were performed to assess the equivalence of the MammaPrint and BluePrint NGS test to the diagnostic microarray test and its reproducibility between different samplings of the same tumor block (surrogate for intratumor heterogeneity), over time (precision) and between different laboratories (interlaboratory agreement). Moreover, the clinical performance of the MammaPrint and BluePrint NGS test was assessed in a set of samples with known clinical outcome, which were previously used to validate the clinical utility of the MammaPrint FDAcleared (Dx) diagnostic test
Q10
. We describe herein the development of targeted RNA NGS MammaPrint/BluePrint tests and their technical and clinical performance compared with the standard microarray-based MammaPrint and BluePrint diagnostic tests.
Materials and Methods

Sample Selection
FFPE samples selected for this study fulfilled the following criteria: i) They complied with the intended use of MammaPrint and BluePrint in vitro diagnostic tests: stage I, stage II, and operable stage III invasive breast cancer, tumor size 5.0 cm, and lymph nodeenegative and one to three lymph nodeepositive patients. ii) They had microarray MammaPrint results covering the entire MammaPrint index range. iii) They had at least five samples for each of the three BluePrint subtypes based on microarray analysis. In addition to these including criteria, FFPE samples selected for the clinical comparison had a minimum follow-up of 5 years from the date of diagnosis.
Targeted RNA-Seq Workflow Overview To develop the targeted RNA NGS MammaPrint/BluePrint test, a modified version of the Agilent SureSelect XT procedure, which combines a strand-specific RNA library with an RNA Enrichment System starting from FFPE tissue, was used. For the general laboratory procedure, please refer to the SureSelect XT RNA Direct Protocol (as per manufacturer's instructions; Agilent Technologies, Santa Clara, CA); and for the Agendia MammaPrint/BluePrint NGS test procedure, please visit the Agendia website (Agendia NV, Amsterdam, the Netherlands). The SureSelect Target Enrichment workflow is a solution-based system using ultralong 120-mer biotinylated cRNA baits (so-called capture probes) to capture regions of interest, enriching them out of a NGS genomic fragment library. The Agilent SureSelect XT technology performs a post-capture indexing where samples are indexed (through a PCR enrichment step) after the capture is performed on each sample individually. After the target enrichment preparation, the cDNA libraries were sequenced using the MiSeq [research use only (RUO) 125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187 and Dx] Illumina sequencers. Subsequently, the expression of the MammaPrint and BluePrint signature genes was assessed using the sequence read count data and translated into the outcome test prediction. Supplemental Figure S1 represents the overall laboratory workflow performed in this study.
NGS Probe Design
First, the Agendia MammaPrint and BluePrint signature genes, previously reported, 3, 10, 18 were translated into capture probes to be used in the Agilent SureSelect XT workflow. The target enrichment panel (ie, capture probes) was designed by first mapping the microarray oligonucleotide sequences to hg19 (ie, human assembly GRCh37), followed by target gene annotation. Genomic locations of probes mapping uniquely to intergenic or noncoding regions were confirmed against hg38 (ie, human assembly GRCh38) using BLAT 19 ; 120-bp capture probes were then tiled across full transcripts based on RefSeq, 20 CCDS, 21 Ensembl, 22 GENCODE, 23 and VEGA 24 reference databases
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. The target regions used to design the SureSelect probes are reported in Supplemental Table S1 . Each signature gene was targeted by multiple probes, from a minimum of 2 up to a maximum of 184 target probes.
The probe selection process resulted in an Agendia bait capture library covering 0.92 megabases of genomic regions. The Agendia bait capture library (alias MammaPrint BluePrint NGS Panel) targets a total of 178 unique genes.
FFPE RNA Quality Assessment and Preparation RNA isolation was performed on four FFPE tissue sections (5 mm thick) with either the RNeasy FFPE kit or AllPrep kit (Qiagen, Valencia, CA) using xylene for deparaffinization, in accordance with the manufacturer's instructions. Isolated FFPE Total RNA had to have 260/280 and 260/230 absorbance ratio values close to 2.0 for both ratios. To assess the quality of the total RNA, the Agilent 2100 Bioanalyzer instrument was used to calculate the DV 200 Q12 metric, which represents the percentage of RNA fragments >200 nucleotides. Samples with DV 200 <20% were excluded from the analysis.
cDNA Library Preparation FFPE Total RNA was chemically fragmented to an appropriate size (approximately 200 nucleotides), and the RNA fragments were bound to random primers. The recommended fragmentation conditions vary, depending on the initial quality of the RNA sample, with lower-quality samples subjected to fragmentation at a lower temperature and for a shorter duration. cDNA was synthesized, and ends were repaired. cDNA was adenylated at the 3 0 end, and Illumina P5/P7 (flow cell binding sites) adapters were ligated. The cDNA adaptereligated library was enriched by PCR amplification. Quality and quantity of the cDNA adaptereligated library were assessed using the Agilent 2100 Bioanalyzer instrument.
RNA Target Enrichment
Prepared cDNA adaptereligated library was hybridized to the Agendia bait capture library overnight. The hybridization reaction combined the prepared cDNA library with the SureSelect hybridization reagents and specific blocking agents. After hybridization was completed (17 to 24 hours), cDNA library/capture library hybrid was captured using streptavidin-coated beads that bind to the biotinylated cRNA baits. Next, the cDNA adaptereligated and captured library was enriched by PCR amplification. The PCR amplification step adds index tags while it amplifies the captured library. Samples (cDNA adaptereligated, captured, and indexed libraries) can then be pooled for multiplexed sequencing. Quality and quantity of the cDNA adaptereligated and captured library were assessed using the Agilent 2100 Bioanalyzer instrument. To proceed with sequencing, at least 1 nmol/L of cDNA adaptereligated and capture library (between 150 and 700 bp) was targeted.
Sequencing cDNA adaptereligated and captured libraries were pooled at equimolar concentration before sequencing. Sample pools of 1, 2, or 4 nmol/L starting concentration were denatured using sodium hydroxide and diluted with hybridization HT1 buffer, as per manufacturer's instructions (Illumina). Samples were single-end sequenced on the Illumina MiSeq or MiSeq DX (RUO mode) instrument at the length of 150 bp using the MiSeq Reagent Kit V3 (150 cycles). A single-end sequencing protocol was chosen because it provided sufficient read count and resolution to assess the expression of the genes in our target panel.
Sequencing Data Analysis
Sequence reads in the FASTQ format were generated and analyzed following a multistep procedure (Supplemental Figure S2) . First, the quality of each FASTQ sequence was assessed using the FASTQC version 0.11.5 software (https:// www.bioinformatics.babraham.ac.uk/projects/fastqc; last accessed November 13, 2018). Next, the reads were trimmed with the Trimmomatic version 0.36 software, 25 and trimmed sequence reads were mapped to the Ensembl GRCh37 human genome using the HISAT2 version 2.0.4 software. 26 HISAT2 output files in a SAM (sequence alignment/map format) were compressed to binary sequence alignment/map files using SAMtools version 1.3.1 27 prior sequence read quantification. Afterward, mapped reads were counted using the feature Counts version 1.5.1 software. 28 FASTQ files of the samples analyzed in this study have been submitted to the European Nucleotide Archive database (https://www.ebi.ac.uk/ena) under the study accession number PRJEB31802.
MammaPrint and BluePrint Outcome Calculation
For each gene in every sample, raw sequence read count was normalized using a count per million normalization method. By correcting the total counts in each sample by the 29 After the data were normalized, MammaPrint and BluePrint indexes were calculated using the same algorithm for current MammaPrint and BluePrint tests as previously described. 3, 6, 8, 10, 30 In brief, the MammaPrint indexes are calculated by taking the expression of the 70 MammaPrint genes for each sample and correlating them to the MammaPrint Risk templates. If the MammaPrint index is >0, the sample is classified as low risk; when the index is 0, then the sample is classified as high risk. Similarly, the BluePrint indexes are calculated by taking the expression of the 80 BluePrint genes and comparing them with the three different templates, one for each of the subtypes (luminal, HER2, and basal types). The subtype with the highest (scaled) correlation is the reported subtype.
Data Analysis and Statistical Analysis
Data were analyzed using the MATLAB software version R2012a (MathWorks, Natick, MA) and RStudio software version 1.1.442, based on R software version 3.4.2
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. Data were visualized using MATLAB software, Multiple Experiment Viewer version 4.8.1 To compare the 70 MammaPrint gene expression levels in different MammaPrint risk groups, for each of the 70 MammaPrint genes, the average NGS and microarray median centered expression of the high-and the low-risk patient samples was calculated separately. NGS and microarray highand low-risk aggregate expressions were compared using Pearson correlation. Similarly, for each of the 80 BluePrint genes, the average NGS and microarray median centered expression of the luminal-, HER2-, and basal-type patient samples was calculated separately. NGS and microarray luminal-, HER2-, and basal-type aggregate expression levels were compared using Pearson correlation.
The equivalence of MammaPrint and BluePrint indexes was determined by a Pearson correlation for assessment of the degree of linear correlation and a Passing-Bablok regression analysis to obtain the regression equation. Scatterplots were used to visually examine the existence of any constant bias in the difference of measurements between samples analyzed with targeted RNA-seq and microarray technologies. Acceptable limits were defined a priori, on the basis of microarray data generated at Agendia between 2012 and 2016 using the Agendia's Test Suite. MammaPrint and BluePrint test outcomes (MammaPrint: high/low risk; BluePrint: luminal, basal, and HER2 types), assessed using targeted RNA-sequencing technology, were compared with the standard microarray diagnostic outcomes using a contingency Concordance, NPA, and PPA should be !90%. The relative stability (reproducibility) is calculated by 100 minus the relative SD, which is the SD measured as percentile of the total MammaPrint or BluePrint NGS dynamic range assessed on a set of 326 samples sequenced in the Agendia laboratories. Clinicopathologic data and clinical outcome data were analyzed using the statistical package SPSS 22.0 for Windows (SPSS Inc., Chicago, IL). All validation experiments to assess technical equivalence, reproducibility, tumor heterogeneity, and clinical performance of the targeted RNA NGS MammaPrint/BluePrint test were designed according to guidelines of the FDA. 31 Interlaboratory reproducibility was tested at the Agendia central laboratory (Amsterdam, the Netherlands; site 1), at University Hospital Leuven (Leuven, Belgium; site 2), and at Curie Institute (Paris, France; site 3).
Study Approval
Only data and not samples were collected for this study. All data and analyses used or performed in this study comply with the current ethical laws of the Netherlands. All patient sample data were anonymized in accordance with national ethical guidelines (Code for Proper Secondary Use of Human Tissues, Dutch Federation of Medical Scientific Societies), and study samples had institutional review board approvals.
Results
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To assess the analytical performance of the MammaPrint/ BluePrint targeted RNA NGS test (referred to as NGS for brevity), a total of 327 FFPE breast cancer samples (Supplemental Table S2 Figure S3 ). These read count estimates indicated that all target genes were expressed in the sample set, and their expression was captured during the target enrichment step. High variation in the gene read counts is expected because of the biological variation in expression of the signature genes, depending on the MammaPrint risk group and BluePrint subtype of the sample.
Gene Expression Comparative Analysis between NGS and Microarray
To assess the correlation between gene expression measured with NGS and microarray, the MammaPrint 70-gene and BluePrint 80-gene expression levels were analyzed in a subset of 204 unique FFPE patient samples for which matched NGS and microarray data were available from the same RNA sample. NGS and microarray normalized expression was median centered per gene separately for each technique (ie, NGS and microarray). A similar strategy has been used previously in a different context, to adjust for platform bias. 
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Technical Equivalence of MammaPrint and BluePrint Results for NGS and Microarray
Equivalence of NGS and microarray technologies was studied by performing both diagnostic tests on a set of 85 FFPE breast cancer samples for MammaPrint and on a set of 98 breast cancer samples for BluePrint (Supplemental Table  S2 ). All samples fulfilled the selection criteria of the study (see Materials and Methods). A and Supplemental Table S3 ). The Bland-Altman analysis showed no bias toward one platform, and the mean difference between the NGS and the microarray indexes was 0.1% of the observed dynamic range for the NGS test; this difference is similar to the technical variance observed using FF tissue on the microarray-to-microarray comparison.
30
Concordance of categorical MammaPrint low-and highrisk classification was 97.6% with an NPA of 94.0% (95% CI, 81.9%e98.5%) and a PPA of 100%. A k score of 0.82 (95% CI, 0.74e0.89) indicated almost perfect agreement. 31 The samples that were discordant in MammaPrint classification results (N Z 2) had indexes close to the classification threshold, with a difference between the NGS and the microarray indexes of 0.018 and to 0.137, respectively. These differences fall within 1 SD from the average index difference A and Supplemental Table S3 ). The correlation between NGS and 621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683 microarray HER2-type indexes was lower than for the luminal and basal-type indexes. This is because of the fact that most samples were not HER2 type and, therefore, the HER2 NGS and microarray indexes of noneHER2-type samples may differ more from each other. In addition, higher variability for the HER2 index is expected because the HER2 subtype is defined by a signature of four genes and expression changes occurring in each of the four HER2 signature genes can have a higher impact on the HER2 signature readout than expression changes occurring in each of the luminal and basal signature genes that are part of a more numerous set (58 luminal signature, 28 basal signature). 10 Of importance, most genes that define the HER2 signature are underexpressed in noneHER2-type samples and, therefore, the measurement precision based on low expressed genes could be poorer. For all three subtypes, the Bland-Altman analysis showed no bias toward one platform, with a mean difference between the NGS and the microarray indexes smaller than the control technical variance observed for FFPE microarray. The mean difference between the NGS and the microarray indexes was 0.8%, 2.8%, and 2.5% of the observed NGS dynamic range for the luminal, HER2, and basal types, respectively (Supplemental Table S4 ). Overall concordance of categorical luminal-, HER2-, and basal-type classification was 100%.
Reproducibility of MammaPrint and BluePrint NGS Results Using Two Independent RNA Isolations from the Same Tumor Tissue Block
Cellular heterogeneity can occur within the same primary tumor (alias intratumor heterogeneity).
36e38 Gene expression analysis results from different parts of the same tumor can, therefore, be variable. To evaluate the possible effect of intratumor heterogeneity, the reproducibility of the MammaPrint/BluePrint NGS test was also assessed between two different RNA isolations from the same FFPE tumor block. 
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Reproducibility of MammaPrint and BluePrint NGS Results Over Time
Reproducibility over time is a key indicator of precision for a diagnostic test. Therefore, three control patient samples (control 1, control 2, control 3) were repeatedly processed and sequenced over a 6-month period, starting from total RNA onwards. Controls 1 and 2 were MammaPrint low risk, and control 3 was MammaPrint high risk. For control 1, there were 26 NGS measurements collected, of which 25 passed the QC assessment; for control 2, there were 23 NGS measurements collected, of which 17 passed the QC assessment; for control 3, there were 16 NGS measurements collected, of which 14 passed the QC assessment.
In this long-term validation experiment, nearly all potential sources of variation are included by default (ie, different operators, reagent batches, and environmental factors).
For both MammaPrint and BluePrint categorical classifications, the concordance was 100% between all the measurements of each control sample. The reproducibility was measured by the relative SD of the samples. MammaPrint showed stable results over time ( Figure 6 ½F6 ½F6
) for all three control patient samples, with relative SDs of 1.5% (control 1, 25 measurements), 2.0% (control 2, 17 measurements), and 1.8% (control 3, 14 measurements). The MammaPrint NGS test showed a reproducibility (ie, relative stability) of 98.5%, 98.0%, and 98.2% in the three control samples, respectively (Supplemental Table S4 ). This reproducibility is slightly higher than using the microarray-based test. 39 Similar to MammaPrint, BluePrint showed stable results over time, with an average relative SD over the three control samples of 1.5% (luminal type), 2.6% (HER2 type), and 1.5% (basal type) (Supplemental Table S4 ). On the basis of these three control samples, the reproducibility of the BluePrint NGS test was 98.5% for the luminal type, 98.4% for the basal type, and 97.4% for the HER2 type (Supplemental Table S4 ). None of the three samples analyzed over time was classified as HER2 subtype and, therefore, the HER2 subtype index reproducibility was not measured. This had no effect on the BluePrint outcomes.
Because there was a higher failure rate for control sample 2, which was isolated with a different RNA isolation method than the other two control samples (ie, Qiagen All Prep kit versus Qiagen RNeasy kit), it was further studied. Twentyeight matched FFPE samples were selected, and each block was sectioned twice; and the first set of four slides was isolated with the RNeasy method, whereas the second set of four slides was isolated with the All Prep isolation methods. Of the 56 samples analyzed (28 pairs), four samples failed for both isolation methods, two for the RNeasy method, and six for the All Prep method. This result would support the idea that All Prep gives a higher failure rate than the RNeasy method. However, larger sample numbers are needed to confirm and elucidate this finding. Additional validation of this hypothesis is still ongoing. Of importance, when looking at the results obtained for 16 RNeasy-AllPrep pairs successfully sequenced, high correlation was observed between the two isolation methods for both MammaPrint NGS indexes and BluePrint NGS indexes for each subtype (MammaPrint Pearson r Z 0.992, luminal-type Pearson r Z 0.997, HER2-type Pearson r Z 0.947, basal-type Pearson r Z 996) ( Figure 4D , Figure 5D , and Supplemental Table S3 ). The 1117  1118  1119  1120  1121  1122  1123  1124  1125  1126  1127  1128  1129  1130  1131  1132  1133  1134  1135  1136  1137  1138  1139  1140  1141  1142  1143  1144  1145  1146  1147  1148  1149  1150  1151  1152  1153  1154  1155  1156  1157  1158  1159  1160  1161  1162  1163  1164  1165  1166  1167  1168  1169  1170  1171  1172  1173  1174  1175  1176  1177  1178  1179 mean difference between the matched NGS indexes was 1.5%, 0.7%, 1.8%, and 0.04% of the observed NGS dynamic range for MammaPrint, BluePrint luminal type, BluePrint HER2 type, and BluePrint basal type, respectively (Supplemental Table S4 ). Concordance of categorical MammaPrint low-and high-risk classification and BluePrint subtype classification between the two isolation methods was 100%.
Reproducibility of MammaPrint and BluePrint NGS Results between Different Laboratories
The main objective of developing a MammaPrint/BluePrint NGS test is the implementation of a decentralized diagnostic setting. Therefore, reproducibility was assessed between different laboratories by processing the same set of 15 FFPE RNA samples in three independent laboratories: Agendia central laboratory (site 1) and two decentralized academic laboratories (sites 2 and 3) (see Materials and Methods). The three sites used a MiSeq instrument with the same setting. One sample analyzed at site 2 did not pass the QC assessment and, therefore, 14 samples were used for the analysis. and Supplemental Table S3 ). For both MammaPrint ( Figure 7A ) and BluePrint ( Figure 7 , B and C), the scatterplot and the Bland-Altman analysis showed no bias toward one of the sites (site 1 versus site 2, site 1 versus site 3), with a mean difference between the matched NGS indexes smaller than the control technical variance (site 1 versus site 2: mean difference in NGS-microarray indexes for MammaPrint was 0.6%, for BluePrint luminal type was 0.8%, for HER2 type was 4.8%, and for basal type was 0.5% of the observed NGS dynamic range; site 1 versus site 3: mean difference in NGS-microarray indexes for MammaPrint was 2.3%, for BluePrint luminal type was 0.7%, for HER2 type was 1.0%, and for basal type was 1.1% of the observed NGS dynamic range) (Supplemental Table S4 ). Concordance of 100% for categorical MammaPrint low-and high-risk classification and BluePrint subtype classification was observed between the three laboratories.
Clinical Performance Comparison
As described above, the NGS-based test proved to be technically equivalent to the microarray diagnostic test, showing high correlation between the NGS-and the microarray-based indexes. Nevertheless, highly correlated continuous values may result in a lower concordance when these continuous variables are presented as binary categories, as is the case for MammaPrint low-and high-risk classification groups. In 1365  1366  1367  1368  1369  1370  1371  1372  1373  1374  1375  1376  1377  1378  1379  1380  1381  1382  1383  1384  1385  1386  1387  1388  1389  1390  1391  1392  1393  1394  1395  1396  1397  1398  1399  1400  1401  1402  1403  1404  1405  1406  1407  1408  1409  1410  1411  1412  1413  1414  1415  1416  1417  1418  1419  1420  1421  1422  1423  1424  1425  1426  1427   1428  1429  1430  1431  1432  1433  1434  1435  1436  1437  1438  1439  1440  1441  1442  1443  1444  1445  1446  1447  1448  1449  1450  1451  1452  1453  1454  1455  1456  1457  1458  1459  1460  1461  1462  1463  1464  1465  1466  1467  1468  1469  1470  1471  1472  1473  1474  1475  1476  1477  1478  1479  1480  1481  1482  1483  1484  1485  1486  1487  1488 particular, samples with a result close to a classification threshold with a small difference between two measurements may still result in a switch in binary outcome. 39 Therefore, the clinical performance of the NGS-based test was assessed in a data set with known clinical outcome. A large series of breast tumors were used from the microarRAy-prognoSTics-inbreast-cancER (RASTER) study, for which 5-year outcome data are available and were used previously to compare different versions of the MammaPrint microarray diagnostic test (ie, MammaPrint FF versus FFPE). 5, 39 All patients were aged 18 to 61 years and had a histologically confirmed invasive adenocarcinoma of the breast (cT1-3N0M0). For 341 samples of the original series of 427, total RNA was available. Because of the age of the samples (on average, 12 years after surgery), 316 were successfully processed with the NGS test (Supplemental Table S2 ). Clinicopathologic characteristics of the 316 patients analyzed with NGS and grouped by MammaPrint risk outcome are reported in Supplemental  Table S5 . The 316 patient subset and the original 427 patient set show similar clinicopathologic characteristics, as confirmed by the P value after testing for difference (Pearson c 2 statistic for categorical variables and U-test
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for continuous variables, P > 0.05) (Supplemental Table S6 shows that the Kaplan-Meier curves are similar between the microarray and NGS results and that MammaPrint NGS high-and low-risk groups significantly differ in 5-year survival, with a log-rank P value smaller than the one observed for MammaPrint microarray (NGS log-rank P Z 0.002 versus microarray log-rank P Z 0.038). Moreover, 5-year survival percentages of distant recurrence-free interval for both the low-and high-risk patient groups were comparable between microarray and NGS, as reported in Table 1 ½T1 ½T1
. Concordance of categorical MammaPrint low-and high-risk classification was 94.0% with an NPA of 96.3% (95% CI, 92.2%e98.3%) and a PPA of 91.4% (95% CI, 85.9%e94.9%). In summary, we show herein that diagnostic testing results using targeted NGS and microarray are comparable and lead to similar clinical performance of both tests in a cohort of patients with known outcome.
Discussion
Gene expressionebased diagnostic tools are increasingly used to assess risk of recurrence in breast cancer. 6 are given for the low-and high-risk groups, separately. DRFI, distant recurrence-free interval; NGS, next-generation sequencing.
MammaPrint and BluePrint Using RNA-Seq
The Journal of Molecular Diagnostics -jmd.amjpathol.org 13   1489  1490  1491  1492  1493  1494  1495  1496  1497  1498  1499  1500  1501  1502  1503  1504  1505  1506  1507  1508  1509  1510  1511  1512  1513  1514  1515  1516  1517  1518  1519  1520  1521  1522  1523  1524  1525  1526  1527  1528  1529  1530  1531  1532  1533  1534  1535  1536  1537  1538  1539  1540  1541  1542  1543  1544  1545  1546  1547  1548  1549  1550  1551   1552  1553  1554  1555  1556  1557  1558  1559  1560  1561  1562  1563  1564  1565  1566  1567  1568  1569  1570  1571  1572  1573  1574  1575  1576  1577  1578  1579  1580  1581  1582  1583  1584  1585  1586  1587  1588  1589  1590  1591  1592  1593  1594  1595  1596  1597  1598  1599  1600  1601  1602  1603  1604  1605  1606  1607  1608  1609  1610  1611  1612 cancer patients through central laboratory services. This limits the availability of these tests, as some countries have legal restrictions on the export of human tissue. To overcome this barrier to clinical use, an RNA-seq kit version of MammaPrint was developed and its reproducibility, stability, and clinical validity were tested. In recent years, RNA NGS technology evolved rapidly, and it is increasingly chosen by genomics laboratories because of its low background, high sensitivity, and reproducibility. 44 Efforts toward the establishment of the best practices for RNA NGS as a clinical test (reproducibility, accuracy, and precision) are ongoing. 2, 45, 46 In light of the potential of the RNA NGS technology for clinical applications, this study was initiated with the objective of translating the current MammaPrint and Blueprint FFPE microarray test to an RNA NGSebased test. A targeted RNA-seq approach was chosen because of the limited size of the gene target panel (approximately 200 genes, which cover 0.9 megabases) and because a target sequencing approach delivers high sequencing depth and high coverage on target. On average, a percentage of reads on target >79% was observed, which indicates a highcapture performance, especially for targeted sequencing of FFPE-derived RNA. 13, 47, 48 Overall, a high concordance was observed between results obtained using NGS and microarray technologies (all >97%). When NGS and microarray results generated from the same FFPE RNA were compared, a discordance rate of 2.4% was observed, which can only be ascribed to the assay-related variation. After combining assay-related variation and intratumor heterogeneity from our study (2.3%), a discordance rate of approximately 5% was obtained, which matches the discordance rate observed for the MammaPrint-fresh microarray test between two biopsy isolations of the same tumor. 30 Interestingly, if it is considered that the concordance between the MammaPrint FFPE and FF test is 91.5% (95% CI, 87%e 95%), 8 it can be concluded indirectly that assay-related variation (NGS versus microarray techniques) is lower than the variation observed between the MammaPrint FF and MammaPrint FFPE microarray tests, when excluding the contribution of intratumor heterogeneity (2.4% FFPE NGS versus FFPE microarray; 3.5% FFPE microarray versus FF predicate microarray). This study suggests that sample preservation method (FF or FFPE) is a bigger contributor to variation than the technological platform (microarray or NGS). This result is in line with the study of Zhang et al, 49 in which they showed that RNA-seq and microarray-based models perform similarly in clinical end point prediction for neuroblastoma patients. In their study, prediction accuracies were most strongly influenced by the nature of the clinical end point, whereas the technological platforms (RNA-seq versus microarray) did not significantly affect performances of the model. 49 Next, the reproducibility of the NGS test was assessed between different central laboratories using different MiSeq instruments. The objective was to measure the reproducibility of the NGS test, excluding the RNA isolation procedure; and therefore, for this experiment, the same total RNA was processed at the different Agendia sites. Again, high correlation was observed in a set of 48 matched RNA samples, between the NGS and microarray MammaPrint and BluePrint indexes (Pearson r coefficients all >0.99) generated at the two central laboratories, as well as high concordance between the categorical MammaPrint and BluePrint classifications (>95%).
In the technical validation studies described so far, a few samples that had a discordant MammaPrint and/or BluePrint NGS classification with respect to the microarray classification were observed. However, all these discordant cases showed an absolute index difference smaller than the microarray technical variance and, therefore, these discordant events could be accepted as part of the expected technical variation of the NGS test.
To assess more extensively the precision of the NGS test, three patient control samples (two low-risk and one high-risk MammaPrint) were repeatedly measured over a 6-month period. Reproducibility of the MammaPrint and BluePrint NGS indexes was >98% (minimum Z 97.0%, maximum Z 99.1%). The data showed that the MammaPrint and BluePrint NGS test is stable over time and that the same result is generated regardless of the operator, reagent lot, day, and other factors switching in the laboratory process.
To assess the reproducibility of the NGS test between decentralized laboratories (ie, not central laboratories), two independent academic European cancer centers (Curie Institute and University Hospital Leuven
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) processed the same set of RNA samples (n Z 15) using the MammaPrint and BluePrint NGS test. Considering that the main reason of developing the MammaPrint/BluePrint test is to enable a decentralized use of diagnostic testing, assessing the reproducibility of the NGS test between independent laboratories is important to assess the feasibility of such a decentralized setting in an academic setting. A 100% concordance was observed between the MammaPrint and BluePrint outcome results obtained at the three sites (Agendia, University Hospital Leuven, Curie Institute), with high correlation (Pearson r > 0.98) between the MammaPrint and BluePrint NGS indexes. This result highlights once again the robustness of the NGS test, and it paves the way for a larger validation study in which samples are processed locally with the NGS kit.
In this study, its clinical performance was also assessed using a set of 316 breast cancer samples with known clinical outcome. Samples that switched between the different platforms may affect the clinical performance of the test. Therefore, 316 samples with known clinical outcome were analyzed and compared with MammaPrint results generated using the microarray platform [FF predicate device, FDA 510(K062694/K070675), same as used for the MINDACT series]. 9 The survival curves of MammaPrint high-and low-risk patients, based on the NGS result, were equivalent to those based on the microarray result. Both NGS and microarray have a significant difference in 5-year distant recurrence-free interval (log-rank P Z 0.002). The NGS kit showed a survival of 97% in the MammaPrint low-risk group in mostly untreated patients. When the MammaPrint risk prediction results obtained with the NGS test were compared with the one based on the reference microarray test, overall high concordance was obtained, with PPA and NPA values both >90%. This result indicates that in nearly all of the cases, patient treatment recommendations based on the NGS result are the same as those based on the microarray result; and the same patient group will be identified for safely forgoing chemotherapy (low-risk patients) or for undergoing necessary chemotherapy treatment (high-risk patients). Discordant results were also observed, as could be expected from the technical equivalence study; however, this is part of the expected technical variation of the NGS test compared with the microarray test.
In summary, results presented herein show that MammaPrint and BluePrint indexes generated with the targeted RNA NGS test are not only technically equivalent to those generated with the microarray FFPE predicate device, but also highly reproducible between centralized laboratories, stable over time, and clinically meaningful. A larger study is required to confirm reproducibility between decentralized laboratories, but preliminary data generated in collaboration with two European academic cancer centers confirm high reproducibility between results from Agendia and external laboratories. The successful translation of the MammaPrint microarray test to an NGS-based test highlights the robustness of the biology behind the MammaPrint test, which underwent several translations over time 6, 8, 30, 39 and still proves to be a reliable tool for personalized medical care. 1802  1803  1804  1805  1806  1807  1808  1809  1810  1811  1812  1813  1814  1815  1816  1817  1818  1819  1820  1821  1822  1823  1824  1825  1826  1827  1828  1829  1830  1831  1832  1833  1834  1835  1836  1837  1838  1839  1840  1841  1842  1843  1844  1845  1846  1847  1848  1849  1850  1851  1852  1853  1854  1855  1856  1857  1858  1859  1860 
